EMA Committee Recommends Full Approval of Imbruvica to Treat Two Blood Cancers

The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending the granting of full marketing approval for Pharmacyclics' Imbruvica (ibrutinib) in the EU.
Pharmaceutical Business Review